Oncopeptides AB (SE:ONCO)

:ONCO

ONCO

Oncopeptides AB

RESEARCH TOOLSreports

Want to see SE:ONCO full AI Analyst Report?

Oncopeptides AB (ONCO) Price & Analysis

9 Followers

ONCO Stock Chart & Stats

kr4.88

>-kr0.01(-0.39%)

At close: Mar 06 4:00 PM EST

kr4.88

>-kr0.01(-0.39%)

Day’s Range― - ―

52-Week Rangekr1.26 - kr6.19

Previous CloseN/A

Volume80.98K

Average Volume (3M)2.28M

Market Cap

kr705.89M

Enterprise Valuekr297.14M

Total Cash (Recent Filing)kr70.15M

Total Debt (Recent Filing)kr124.23M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding387,851,200

10 Day Avg. Volume1,913,694

30 Day Avg. Volume2,284,999

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)-18.53

Price to Sales (P/S)15.35

P/FCF Ratio-4.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)kr150.00M

Bulls Say, Bears Say

Bulls Say

Very High Gross MarginAn exceptionally high gross margin (~97%) signals strong product-level profitability and durable unit economics. As commercial volumes scale, fixed commercial and R&D costs can be absorbed, enabling operating leverage and materially improving cash generation potential over the medium term.

Strong Revenue Rebound And AdoptionTriple-digit revenue growth and over 600 treated patients demonstrate genuine market uptake after EMA approval. Established commercial teams in Italy, Spain and Germany provide a scalable European platform that can steadily increase sales under market exclusivity, supporting sustainable revenue growth.

Promising Glioblastoma Preclinical ProgramGLIOPEP preclinical results showing near-complete brain bioavailability and BBB penetration offer a structurally meaningful pipeline opportunity. If Phase 0 confirms human BBB passage, this could expand indications, diversify revenue and extend product lifecycle beyond current multiple myeloma commercialization.

Bears Say

Negative Equity / Weak CapitalizationEquity turning negative is a durable capital-structure concern. It reduces borrowing capacity, distorts leverage ratios, raises refinancing and covenant risk, and increases likelihood of dilutive funding — limiting strategic flexibility and increasing financial vulnerability over the medium term.

Persistent Heavy Cash Burn And Funding RelianceSustained multi-year negative operating and free cash flow forces recurring external financing. The planned SEK 200m rights issue highlights dependency on dilutive capital to fund commercialization and planned glioblastoma studies, constraining long-term investment and magnifying execution risk if markets tighten.

Commercial Execution & Partnership UncertaintyMarket-access setbacks, slower uptake in key European markets and uncertain international partnerships indicate durable execution risk. Reliance on regional recovery and third-party partners can delay broader revenue diversification, prolong commercialization costs, and defer sustainable cash-flow generation.

Oncopeptides AB News

Oncopeptides AGM Backs Incentive Schemes and Expands Capital-Raising Mandate

Oncopeptides AB ( ($SE:ONCO) ) has provided an announcement. Oncopeptides’ Annual General Meeting approved the 2025 annual report,...

2d ago

Oncopeptides’ Pepaxti Shows Strong Phase 2 Data in Myeloma Patients With Renal Impairment

Oncopeptides AB ( ($SE:ONCO) ) has shared an update. Oncopeptides has reported Phase 2 BRIDGE study results showing...

3d ago

Oncopeptides Wins Norwegian Green Light for Pioneering Glioblastoma Trial

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides has secured regulatory and ethics approval...

4d ago

Oncopeptides showcases new Pepaxti data to bolster multiple myeloma positioning

Oncopeptides AB ( ($SE:ONCO) ) has shared an announcement. Oncopeptides AB announced new clinical and real-world evidence for...

10d ago

Oncopeptides posts strong Q1 sales growth as Pepaxti momentum builds in Europe

Oncopeptides AB ( ($SE:ONCO) ) has issued an announcement. Oncopeptides reported a strong start to 2026, with first-quarter...

10d ago

Oncopeptides Targets Third-Line Multiple Myeloma Indication to Boost Pepaxti Growth

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an announcement. Oncopeptides plans to seek a Type II variation from...

12d ago

Oncopeptides Sets May 13 Webcast for Q1 2026 Results

Oncopeptides AB ( ($SE:ONCO) ) has provided an update. Oncopeptides AB, a Stockholm-listed biotech focused on targeted therapies...

17d ago

Oncopeptides Marks Growth Phase as 2025 Annual Report Highlights Pepaxti Momentum

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an announcement. Oncopeptides AB, a Stockholm-listed biotech focused on targeted cancer...

25d ago

Oncopeptides Sets May Date and Rules for 2026 AGM Participation

Oncopeptides AB ( ($SE:ONCO) ) just unveiled an update. Oncopeptides AB has called its Annual General Meeting for...

1M ago

Oncopeptides Showcases Promising NK-Cell Engager Data for Multiple Myeloma at AACR 2026

Oncopeptides AB ( ($SE:ONCO) ) has provided an announcement. Oncopeptides AB announced that new preclinical data from its...

1M ago

ONCO FAQ

What was Oncopeptides AB’s price range in the past 12 months?

Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.19 in the past 12 months.

What is Oncopeptides AB’s market cap?

Oncopeptides AB’s market cap is kr705.89M.

When is Oncopeptides AB’s upcoming earnings report date?

Oncopeptides AB’s upcoming earnings report date is Aug 27, 2026 which is in 96 days.

How were Oncopeptides AB’s earnings last quarter?

Oncopeptides AB released its earnings results on May 13, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.12.

Is Oncopeptides AB overvalued?

According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oncopeptides AB pay dividends?

Oncopeptides AB does not currently pay dividends.

What is Oncopeptides AB’s EPS estimate?

Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncopeptides AB have?

Oncopeptides AB has 387,851,200 shares outstanding.

What happened to Oncopeptides AB’s price movement after its last earnings report?

Oncopeptides AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 38.715%.

Which hedge fund is a major shareholder of Oncopeptides AB?

Currently, no hedge funds are holding shares in SE:ONCO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncopeptides AB

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.